Table 2.

Frequency distribution of clinical data in study participants according to reproductive organ involvement

Variable		ROI		P value
		No	Yes
		n (%)	n (%)
History of Smoking	No (n=121)	101 (83.5)	20 (16.5)	0.765**
	Yes (n=22)	18 (81.8)	4 (18.2)
Clinical T stage (TURT)	T2 (n=102)	89 (87.3)	13 (12.7)	0.042*
	T3 (n=41)	30 (73.2)	11 (26.8)
Number of Tumors	Single (n=39)	34 (87.2)	5 (12.8)	0.437*
	Multiple (n=104)	85 (81.7)	19 (18.3)
Tumor location	Other (n=102)	94 (92.2)	8 (7.8)	<0.001*
	Trigone or bladder neck (n=41)	25 (61)	16 (39)
Maximum tumor size	≤5 cm (n=102)	91 (89.2)	11 (10.8)	0.002*
	>5 cm (n=41)	28 (68.3)	13 (31.7)
Concomitant CIS	No (n=106)	93 (87.7)	13 (12.3)	0.014*
	Yes (n=37)	26 (70.3)	11 (29.7)
Lymphovascular invasion	No (n=82)	75 (91.5)	7 (8.5)	0.002*
	Yes (n=61)	44 (72.1)	17 (27.9)
Preoperative Hydronephrosis	No (n=93)	86 (92.5)	7 (7.5)	<0.001**
	Yes (n=50)	33 (66)	17 (34)
Variable		mean±SD	mean±SD	P value
Age (year)		69.42±11.03	67.96±8.35	0.540***
BMI (Kg/m2)		24.91±3.54	25.50±3.50	0.456***

TURT: Trans-urethral resection of tumor; ROI: Reproductive organ involvement; BMI: Body mass index; CIS: Carcinoma in situ; SD: Standard deviation;

^*Chi square;

^**Fisher exact test;

^***Independent t test;

P≤0.05 was considered statistically significant.